124 related articles for article (PubMed ID: 19725798)
1. Cost of illness associated with Niemann-Pick disease type C in the UK.
Imrie J; Galani C; Gairy K; Lock K; Hunsche E
J Med Econ; 2009 Sep; 12(3):219-29. PubMed ID: 19725798
[TBL] [Abstract][Full Text] [Related]
2. Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: a 5-year update from the UK clinical database.
Imrie J; Heptinstall L; Knight S; Strong K
BMC Neurol; 2015 Dec; 15():257. PubMed ID: 26666848
[TBL] [Abstract][Full Text] [Related]
3. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.
Bassi A; Dodd S; Williamson P; Bodger K
Gut; 2004 Oct; 53(10):1471-8. PubMed ID: 15361497
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
5. Health economic evaluation of plasma oxysterol screening in the diagnosis of Niemann-Pick Type C disease among intellectually disabled using discrete event simulation.
van Karnebeek CD; Mohammadi T; Tsao N; Sinclair G; Sirrs S; Stockler S; Marra C
Mol Genet Metab; 2015 Feb; 114(2):226-32. PubMed ID: 25095726
[TBL] [Abstract][Full Text] [Related]
6. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.
Guest JF; Cookson RF
Pharmacoeconomics; 1999 Jun; 15(6):597-610. PubMed ID: 10538332
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
8. The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis.
Divino V; Dekoven M; Warner JH; Giuliano J; Anderson KE; Langbehn D; Lee WC
J Med Econ; 2013 Aug; 16(8):1043-50. PubMed ID: 23789925
[TBL] [Abstract][Full Text] [Related]
9. Annual cost of erectile dysfunction to UK Society.
Plumb JM; Guest JF
Pharmacoeconomics; 1999 Dec; 16(6):699-709. PubMed ID: 10724796
[TBL] [Abstract][Full Text] [Related]
10. Costs and quality of life of multiple sclerosis in the United Kingdom.
Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S96-104. PubMed ID: 17310341
[TBL] [Abstract][Full Text] [Related]
11. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
12. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
13. Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study.
Wraith JE; Guffon N; Rohrbach M; Hwu WL; Korenke GC; Bembi B; Luzy C; Giorgino R; Sedel F
Mol Genet Metab; 2009 Nov; 98(3):250-4. PubMed ID: 19616462
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
Phanthunane P; Whiteford H; Vos T; Bertram M
J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
[TBL] [Abstract][Full Text] [Related]
15. The societal cost of schizophrenia in Sweden.
Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
[TBL] [Abstract][Full Text] [Related]
16. [Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China].
Liang S; Zhang SX; Ma QS; Xiao HW; Lü QY; Xie X; Mei SJ; Hu DS; Zhou BP; Li B; Chen JF; Cui FQ; Wang FZ; Liang XF
Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1340-5. PubMed ID: 21223660
[TBL] [Abstract][Full Text] [Related]
17. Annual cost of bipolar disorder to UK society.
Das Gupta R; Guest JF
Br J Psychiatry; 2002 Mar; 180():227-33. PubMed ID: 11872515
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.
Lee PP; Walt JG; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD; Katz LJ; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL
Arch Ophthalmol; 2006 Jan; 124(1):12-9. PubMed ID: 16401779
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
20. Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.
Weidlich D; Andersson FL; Oelke M; Drake MJ; Jonasson AF; Guest JF
Eur J Health Econ; 2017 Jul; 18(6):761-771. PubMed ID: 27678109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
